AngioGenetics AB and Tumour Biology Centre Freiburg collaborate on the exploration of angiogenesis inhibitors for cancer treatment.: An article from: BIOTECH Patent News

This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on May 1, 2004. The length of the article is 2286 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: AngioGenetics AB and Tumour Biology Centre Freiburg collaborate on the exploration of angiogenesis inhibitors for cancer treatment.
Publication:BIOTECH Patent News (Newsletter)
Date: May 1, 2004
Publisher: Biotech Patent News
Volume: 18 Issue: 5

Distributed by Thomson Gale